With helpful use of the medication, an enemy of COVID-19, 2-Deoxy-glucose (2-DG) has been created by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defense Research and Development Organization (DRDO), as a team with Dr Reddy's Laboratories (DRL), Hyderabad. Clinical preliminary outcomes have shown that this particle helps in quicker recuperation of hospitalized patients and diminishes supplemental oxygen reliance. Higher extent of patients treated with 2-DG showed RT-PCR negative change in COVID patients.
An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. The drug will help in faster recovery of Covid-19 patients. https://t.co/HBKdAnZCCP pic.twitter.com/8D6TDdcoI7— DRDO (@DRDO_India) May 8, 2021
The DRDO, alongside its industry accomplice DRL, Hyderabad, begun the clinical preliminaries to test the security and viability of the medication in COVID-19 patients. In Phase-II preliminaries (counting portion running) led during May to October 2020, the medication was discovered to be protected in COVID-19 patients and showed huge improvement in their recuperation. Stage IIa was directed in six emergency clinics and Phase IIb (portion running) clinical preliminary was led at 11 medical clinics everywhere on the country. Stage II preliminary was led on 110 patients.
The comparable pattern was seen in patients matured over 65 years. On May 01, 2021, DCGI conceded consent for Emergency Use of this medication as assistant treatment in moderate to serious COVID-19 patients. The medication comes in powder structure in sachet, which is taken orally by dissolving it in water. It amasses in the infection contaminated cells and forestalls infection development by halting viral amalgamation and energy creation.
The organization also posted on their social media about the same as-
In the present second COVID-19 wave, countless patients are confronting extreme oxygen reliance and need hospitalization. The medication is required to save valuable lives because of the component of activity of the medication in contaminated cells. This additionally decreases the emergency clinic stay of COVID-19 patients.